@article {Menaa:2012:0929-8673:5854,
title = "Development of Mitotane Lipid Nanocarriers and Enantiomers: Two-in-One Solution to Efficiently Treat Adreno-Cortical Carcinoma",
journal = "Current Medicinal Chemistry",
parent_itemid = "infobike://ben/cmc",
publishercode ="ben",
year = "2012",
volume = "19",
number = "34",
publication date ="2012-12-01T00:00:00",
pages = "5854-5862",
itemtype = "ARTICLE",
issn = "0929-8673",
url = "https://www.ingentaconnect.com/content/ben/cmc/2012/00000019/00000034/art00009",
doi = "doi:10.2174/092986712804143376",
keyword = "mitotane synthesis, endocrine cancer chemotherapy, nanostructured lipid carriers, simulated moving bed chromatography, translational medicine, supercritical fluid chromatography, nanomedicine, mitotane pharmacology, lysodren®, Adreno-cortical carcinoma, solid lipid nanoparticles, mitotane enantiomers, chiral separation, medicinal chemistry, cancer endocrinology",
author = "Menaa, F. and Menaa, B.",
abstract = "Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with a poor prognosis. Treatment options for advanced ACC are limited. Indeed, radical tumor resection can lead to local or metastatic recurrence, and mitotane (Lysodren	extregistered), the only recognized adrenolytic drug, offers
modest response rates, notably due to some of its physico-chemical and pharmacological properties (i.e. hydrophobicity, low bioavailability). Meantime, high cumulative doses of Lysodren	extregistered usually cause systemic toxicities. To reduce adverse health effects, the search of safe and efficient
mitotane nano-formulations as well as the full characterization and testing of its enantiomers can represent valuable therapeutic options. Interestingly, recent investigations showed that solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) could considerably improve the
efficacy of mitotane (i.e. enhanced solubility and bioavailability, progressive release of the loaded drug into blood and targeted tissues) as well as its safety (i.e. lower toxicity, higher biocompatibility). These two nano-carriers for mitotane delivery and targeting are of particular interest
over other polymeric particles (i.e. low-cost, efficient and simple scaling to an industrial production level following green methods). Besides, emerging studies suggested that the S-(-)- mitotane is more potent than the R-(+)-mitotane for ACC treatment. Therefore, the production of pure
and active S-(-)-mitotane might offer synergic or additive benefits for ACC patients when combined to solid lipid-based nanocarriers. In this review, we first provide an updated overview of the ACC disease before emphasizing on the promising mitotane drug nano-systems, as well as on the separation,
purification and production of single mitotane enantiomer using state-of-art chromatographic-based methods.",
}